Technology | January 28, 2014

FDA Clears AtheroMed’s Phoenix Atherectomy System For Peripheral Artery Disease

AtheroMed Phoenix Atherectomy System Device Peripheral Artery Disease PAD
January 28, 2014 — AtheroMed, a developer of catheter technologies for treating peripheral artery disease (PAD), received clearance from the U.S. Food and Drug Administration (FDA) to market the Phoenix Atherectomy System. This system allows physicians to treat PAD with a low profile atherectomy catheter that continuously removes diseased material as it is debulked and does not require specialized capital equipment.
 
"Peripheral artery disease, especially lesions located below the knee, can be challenging to treat, even with currently available technologies," said Thomas Davis, M.D., director of the cardiac catheterization lab and director of peripheral interventions and disease, St. John Hospital and Medical Center, Detroit, Mich. "My experience with the Phoenix device during the EASE clinical study was extremely positive, and I am excited that the device is now available as it will allow me to debulk small vessels that I may not have been able to treat in the past."
 
The Phoenix Atherectomy System is a peripheral atherectomy over-the wire system that uses a rotating, front-cutting element located at the distal tip of the catheter to shave material directly into the catheter. The debulked material is then continuously captured and removed by an internal Archimedes Screw running the length of the catheter. The Phoenix Atherectomy System is available in multiple sizes to treat diseased vessels from the thigh to the foot with catheter sizes down to 1.8 mm in diameter with a 5-French profile.
 
For more information: www.atheromedinc.com

Related Content

FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-...
New Report Says Concept Medical Positioned to Disrupt Peripheral Market
News | Peripheral Artery Disease (PAD) | August 27, 2019
Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)...
PAD Intervention Patients on Statins Less Likely to Face Amputation
News | Peripheral Artery Disease (PAD) | August 23, 2019
Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after surgical...
Concept Medical Granted FDA Breakthrough Device Designation for MagicTouch PTA Sirolimus Coated Balloon
News | Peripheral Artery Disease (PAD) | August 14, 2019
Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug...
New AHA Statement Highlights Need for Early Diagnosis, Treatment With Critical Limb IschemiaCTA image of a patient with severe peripheral artery disease (PAD) viewed on a tablet device using Siemens syngo.via webviewer.

CTA image of a patient with severe peripheral artery disease (PAD) viewed on a tablet device using Siemens syngo.via webviewer. PAD can lead to CLI.

News | Peripheral Artery Disease (PAD) | August 13, 2019
Non-invasive techniques and devices for assessing blood flow and other diagnostic considerations for people with ...
Endovascular-first Approach Equal to Open Surgery in Avoiding Amputation for Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | August 01, 2019
Less-invasive procedures to open severely clogged leg arteries were as good at helping people survive and avoid...
Annual U.S. Economic Burden of Critical Limb Ischemia Exceeds $200 Billion
News | Peripheral Artery Disease (PAD) | July 17, 2019
A new analysis published by The Sage Group LLC concludes that the all-cause cost of critical limb ischemia (CLI)...
Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S.
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Overlay Init